Targeting both viral and host determinants of human immunodeficiency virus entry, using a new lentiviral vector coexpressing the T20 fusion inhibitor and a selective CCL5 intrakine

Human Gene Therapy Methods

Volumn 25, Issue 4, 2014, Pages 232-240

  Petit, Nicolas ^a,b,c   Dorgham, Karim ^a,b,c   Levacher, Béatrice ^d   Burlion, Aude ^a,b,c   Gorochov, Guy ^a,b,e   Marodon, Gilles ^a,b,c  

^a SORBONNE UNIVERSITÉ   (France)

^b Assistance publique Hôpitaux de Paris   (France)

^c CNRS   (France)

^d INSERM   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; ENFUVIRTIDE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INTRAKINE; LENTIVIRUS VECTOR; UNCLASSIFIED DRUG; C46 HIV-1 FUSION INHIBITORY PEPTIDE; HYBRID PROTEIN; RANTES;

ARTICLE; CELL DEATH; CELL SELECTION; CELL SURFACE; DNA EXTRACTION; FLOW CYTOMETRY; HEK293 CELL LINE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; LIFE CYCLE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; CELL CULTURE; CYTOLOGY; GENE THERAPY; GENE VECTOR; GENETICS; HIV INFECTIONS; LENTIVIRINAE; METABOLISM; PHYSIOLOGY; T LYMPHOCYTE; VIROLOGY; VIRUS ENTRY; VIRUS REPLICATION;

CELLS, CULTURED; CHEMOKINE CCL5; GENETIC THERAPY; GENETIC VECTORS; HEK293 CELLS; HIV INFECTIONS; HIV-1; HUMANS; LENTIVIRUS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 84906683585     PISSN: 19466536     EISSN: 19466544     Source Type: Journal    
DOI: 10.1089/hgtb.2014.034     Document Type: Article

References (31)

1. Allers, K., Hütter, G., Hofmann, J., et al. (2011). Evidence for the cure of HIV infection by CCR5D32/D32 stem cell transplantation. Blood 117, 2791-2799.
2. Anderson, J., Li, M.-J., Palmer, B., et al. (2007). Safety and efficacy of a lentiviral vector containing three anti-HIV genes-CCR5 ribozyme, tat-rev siRNA, and TAR decoy-in SCID-hu mouse-derived T cells. Mol. Ther. 15, 1182-1188.
3. Deng, H., Liu, R., Ellmeier, W., et al. (1996). Identification of a major co-receptor for primary isolates of HIV-1 [see comments]. Nature 381, 661-666.
4. De Rijck, J., Vandekerckhove, L., Gijsbers, R., et al. (2006). Overexpression of the lens epithelium-derived growth factor/p75 integrase binding domain inhibits human immunodeficiency virus replication. J. Virol. 80, 11498-11509.
5. Didigu, C.A., Wilen, C.B., Wang, J., et al. (2014). Simultaneous zinc-finger nuclease editing of the HIV coreceptors CCR5 and CXCR4 protects CD4+ T cells from HIV-1 infection. Blood 123, 61-69.
6. DiGiusto, D.L., Krishnan, A., Li, L., et al. (2010). RNA-based gene therapy for HIV with lentiviral vector-modified CD34+ : Cells in patients undergoing transplantation for AIDS-related lymphoma. Sci. Transl. Med. 2, 36ra43.
7. Doitsh, G., Galloway, N.L.K., Geng, X., et al. (2014). Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature 505, 509-514.
8. Dupuy, F.P., Mouly, E., Mesel-Lemoine, M., et al. (2005). Lentiviral transduction of human hematopoietic cells by HIV-1-and SIV-based vectors containing a bicistronic cassette driven by various internal promoters. J. Gene Med. 7, 1158-1171.
9. Egelhofer, M., Brandenburg, G., Martinius, H., et al. (2004). Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J. Virol. 78, 568-575.
10. Greenberg, M.L., and Cammack, N. (2004). Resistance to enfuvirtide, the first HIV fusion inhibitor. J. Antimicrob. Chemother. 54, 333-340.
11. Hartley, O., Dorgham, K., Perez-Bercoff, D., et al. (2003). Human immunodeficiency virus type 1 entry inhibitors selected on living cells from a library of phage chemokines. J. Virol. 77, 6637-6644.
12. Heredia, A., Gilliam, B., DeVico, A., et al. (2007). CCR5 density levels on primary CD4 T cells impact the replication and enfuvirtide susceptibility of R5 HIV-1. AIDS 21, 1317-1322.
13. Hildinger, M., Dittmar, M.T., Schult-Dietrich, P., et al. (2001). Membrane-anchored peptide inhibits human immunodeficiency virus entry. J. Virol. 75, 3038-3042.
14. Holt, N., Wang, J., Kim, K., et al. (2010). Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat. Biotechnol. 28, 839-847.
15. Hutter, G., Nowak, D., Mossner, M., et al. (2009). Long-term control of HIV by CCR5 D32/D32 stem-cell transplantation. N. Engl. J. Med. 360, 692-698.
16. Jin, H., Kagiampakis, I., Li, P., et al. (2010). Structural and functional studies of the potent anti-HIV chemokine variant P2-RANTES. Proteins 78, 295-308.
17. Judge, A.D., Sood, V., Shaw, J.R., et al. (2005). Sequencedependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23, 457-462.
18. Kimpel, J., Braun, S.E., Qiu, G., et al. (2010). Survival of the fittest: Positive selection of CD4+ T cells expressing a membrane-bound fusion inhibitor following HIV-1 infection. PLoS One 5, e12357.
19. Lohrengel, S., Hermann, F., Hagmann, I., et al. (2005). Determinants of human immunodeficiency virus type 1 resistance to membrane-anchored gp41-derived peptides. J. Virol. 79, 10237-10246.
20. Marodon, G., Warren, D., Filomio, M.C., et al. (1999). Productive infection of double negative T cells with HIV in vivo. Proc. Natl. Acad. Sci. U.S.A. 96, 11958-11963.
21. Marodon, G., Mouly, E., Blair, E.J., et al. (2003). Specific transgene expression in human and mouse CD4+ cells using lentiviral vectors with regulatory sequences from the CD4 gene. Blood 101, 3416-3423.
22. Pattanayak, V., Ramirez, C.L., Joung, J.K., et al. (2011). Revealing off-target cleavage specificities of zinc-finger nucleases by in vitro selection. Nat. Methods 8, 765-770.
23. Perez, E.E., Riley, J.L., Carroll, R.G., et al. (2005). Suppression of HIV-1 infection in primary CD4 T cells transduced with a self-inactivating lentiviral vector encoding a membrane expressed gp41-derived fusion inhibitor. Clin. Immunol. 115, 26-32.
24. Perez, E.E., Wang, J., Miller, J.C., et al. (2008). Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat. Biotechnol. 26, 808-816.
25. Peterson, C.W., Younan, P., Jerome, K.R., et al. (2013). Combinatorial anti-HIV gene therapy: Using a multipronged approach to reach beyond HAART. Gene Ther. 20, 695-702.
26. Qin, X.F., An, D.S., Chen, I.S., et al. (2003). Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc. Natl. Acad. Sci. U.S.A. 100, 183-188.
27. Robbins, M., Judge, A., Ambegia, E., et al. (2008). Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum. Gene Ther. 19, 991-999.
28. Swan, C.H., Buhler, B., Tschan, M.P., et al. (2006). T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery. Gene Ther. 13, 1480-1492.
29. Tebas, P., Stein, D., Tang, W.W., et al. (2014). Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 370, 901-910.
30. Walker, J.E., Chen, R.X., McGee, J., et al. (2012). Generation of an HIV-1-resistant immune system with CD34 + : Hematopoietic stem cells transduced with a triplecombination anti-HIV lentiviral vector. J. Virol. 86, 5719-5729.
31. Yang, A.G., Bai, X., Huang, X.F., et al. (1997). Phenotypic knockout of HIV type 1 chemokine coreceptor CCR-5 by intrakines as potential therapeutic approach for HIV-1 infection. Proc. Natl. Acad. Sci. U.S.A. 94, 11567-11572.